nach oben

Tumor Biology

Erschienen in:

01.10.2014 | Research Article

Upregulation of SYF2 in esophageal squamous cell carcinoma promotes tumor cell proliferation and predicts poor prognosis

verfasst von: Junya Zhu, Lili Ji, Jianguo Zhang, Lei Yang, Chengqi Guan, Yayun Wang, Jia Zhu, Li Liang, Runzhou Ni

Erschienen in: Tumor Biology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

SYF2, also known as CCNDBP1-interactor or p29, is reported in pre-mRNA splicing and cell cycle progression. However, the role of SYF2 in esophageal squamous cell carcinoma (ESCC) development remains elusive. In the present study, Western blot and immunohistochemistry assays demonstrated that SYF2 was overexpressed in ESCC tumor tissues and cell lines. In addition, immunohistochemistry analysis revealed that SYF2 expression was positively correlated with tumor grade and predicted poor prognosis of ESCC. In vitro studies using serum starvation-refeeding experiment and SYF2-siRNA transfection assay demonstrated that SYF2 expression promoted proliferation of ESCC cells, while SYF2 knockdown led to decreased cell growth rate and colony formation resulted from growth arrest of cell cycle at G0/G1 phase. Furthermore, our results indicated that SYF2 can down-regulate the sensitivity of ESCC cells for cisplatin. Our findings for the first time supported that SYF2 might play an important role in the regulation of ESCC proliferation and would provide a novel therapeutic strategy against human ESCC.

Buchanan G, Ricciardelli C, Harris JM, Prescott J, Yu ZC, Jia L, et al. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res. 2007;67(20):10087–96. doi:10.1158/0008-5472.CAN-07-1646.CrossRefPubMed

Ciccarelli RB, Solomon MJ, Varshavsky A, Lippard SJ. In vivo effects of cis- and trans-diamminedichloroplatinum (II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry. 1985;24(26):7533–40.CrossRefPubMed

Hulleman E, Boonstra J. Regulation of G1 phase progression by growth factors and the extracellular matrix. Cell Mol Life Sci CMLS. 2001;58(1):80–93.CrossRefPubMed

Malumbres M, Carnero A. Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res. 2003;5:5–18.PubMed

Tashima Y, Hamada H, Okamoto M, Hanai T. Prediction of key factor controlling G1/S phase in the mammalian cell cycle using system analysis. J Biosci Bioeng. 2008;106(4):368–74. doi:10.1263/jbb.106.368.CrossRefPubMed

Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7(5):812–21.CrossRefPubMed

Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A. 1990;87(24):9958–61.CrossRefPubMedPubMedCentral

Adelaide J, Monges G, Derderian C, Seitz JF, Birnbaum D. Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br J Cancer. 1995;71(1):64–8.CrossRefPubMedPubMedCentral

Shinozaki H, Ozawa S, Ando N, Tsuruta H, Terada M, Ueda M, et al. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res Off J Am Assoc Cancer Res. 1996;2(7):1155–61.

10.

Xu W, Cao M, Zheng H, Tan X, Li L, Cui G, et al. Upregulation of SYF2 is associated with neuronal apoptosis caused by reactive astrogliosis to neuroinflammation. J Neurosci Res. 2014;92(3):318–28. doi:10.1002/jnr.23312.CrossRefPubMed

11.

Chang MS, Chang CL, Huang CJ, Yang YC. p29, a novel GCIP-interacting protein, localizes in the nucleus. Biochem Biophys Res Commun. 2000;279(2):732–7. doi:10.1006/bbrc.2000.3992.CrossRefPubMed

12.

Ben-Yehuda S, Dix I, Russell CS, McGarvey M, Beggs JD, Kupiec M. Genetic and physical interactions between factors involved in both cell cycle progression and pre-mRNA splicing in Saccharomyces cerevisiae. Genetics. 2000;156(4):1503–17.PubMedPubMedCentral

13.

Chang MS, Chen CY, Yeh HI, Fan CC, Huang CJ, Yang YC. Cloning, expression, and genomic organization of mouse mp29 gene. Biochem Biophys Res Commun. 2002;299(2):241–6.CrossRefPubMed

14.

Chu PC, Yang YC, Lu YT, Chen HT, Yu LC, Chang MS. Silencing of p29 affects DNA damage responses with UV irradiation. Cancer Res. 2006;66(17):8484–91. doi:10.1158/0008-5472.CAN-05-3229.CrossRefPubMed

15.

Chu PC, Wang TY, Lu YT, Chou CK, Yang YC, Chang MS. Involvement of p29 in DNA damage responses and Fanconi anemia pathway. Carcinogenesis. 2009;30(10):1710–6. doi:10.1093/carcin/bgp204.CrossRefPubMed

16.

Dahan O, Kupiec M. Mutations in genes of Saccharomyces cerevisiae encoding pre-mRNA splicing factors cause cell cycle arrest through activation of the spindle checkpoint. Nucleic Acids Res. 2002;30(20):4361–70.CrossRefPubMedPubMedCentral

17.

Chen CH, Chu PC, Lee L, Lien HW, Lin TL, Fan CC, et al. Disruption of murine mp29/Syf2/Ntc31 gene results in embryonic lethality with aberrant checkpoint response. PLoS One. 2012;7(3):e33538. doi:10.1371/journal.pone.0033538.CrossRefPubMedPubMedCentral

18.

Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union internationale contre le cancer and the american joint committee on cancer. Cancer. 1997;80(9):1803–4.CrossRefPubMed

19.

Xue Q, Lv L, Wan C, Chen B, Li M, Ni T, et al. Expression and clinical role of small glutamine-rich tetratricopeptide repeat (TPR)-containing protein alpha (SGTA) as a novel cell cycle protein in NSCLC. J Cancer Res Clin Oncol. 2013;139(9):1539–49. doi:10.1007/s00432-013-1474-5.CrossRefPubMed

20.

Liu Y, Lv L, Xue Q, Wan C, Ni T, Chen B, et al. Vacuolar protein sorting 4B, an ATPase protein positively regulates the progression of NSCLC via promoting cell division. Mol Cell Biochem. 2013;381(1–2):163–71. doi:10.1007/s11010-013-1699-2.CrossRefPubMed

21.

Liu Y, Chen Y, Lu X, Wang Y, Duan Y, Cheng C, et al. SCYL1BP1 modulates neurite outgrowth and regeneration by regulating the Mdm2/p53 pathway. Mol Biol Cell. 2012;23(23):4506–14. doi:10.1091/mbc.E12-05-0362.CrossRefPubMedPubMedCentral

22.

Morris GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem. 1989;264(23):13856–64.PubMed

23.

Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–79. doi:10.1038/sj.onc.1206933.CrossRefPubMed

24.

Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res Off J Am Assoc Cancer Res. 2001;7(12):4220–9.

25.

Takano S, Shiomoto S, Inoue KY, Ino K, Shiku H, Matsue T. Electrochemical approach for the development of a simple method for detecting cell apoptosis based on caspase-3 activity. Anal Chem. 2014. doi:10.1021/ac403394z.

26.

Fan JH, Feng GG, Huang L, Tang GD, Jiang HX, Xu J. Naofen promotes TNF-alpha-mediated apoptosis of hepatocytes by activating caspase-3 in lipopolysaccharide-treated rats. World J Gastroenterol WJG. 2014;20(17):4963–71. doi:10.3748/wjg.v20.i17.4963.CrossRefPubMed

27.

Yang S, Wang L, Kong Q. Depression of focal adhesion kinase induces apoptosis in rat osteosarcoma OSR-6 cells in a caspase-dependent pathway. Cell Biochem Biophys. 2014. doi:10.1007/s12013-014-9979-3.PubMedCentral

28.

Zhu H, Wang Q, Hu C, Zhang W, Quan L, Liu M, et al. High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2011;32(6):1147–53. doi:10.1007/s13277-011-0217-y.CrossRef

29.

Vincent K, Wang Q, Jay S, Hobbs K, Rymond BC. Genetic interactions with CLF1 identify additional pre-mRNA splicing factors and a link between activators of yeast vesicular transport and splicing. Genetics. 2003;164(3):895–907.PubMedPubMedCentral

30.

Witzel II, Koh LF, Perkins ND. Regulation of cyclin D1 gene expression. Biochem Soc Trans. 2010;38(Pt 1):217–22. doi:10.1042/BST0380217.CrossRefPubMed

31.

Ma W, Stafford LJ, Li D, Luo J, Li X, Ning G, et al. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis. J Cell Biochem. 2007;100(6):1376–86. doi:10.1002/jcb.21140.CrossRefPubMed

Titel: Upregulation of SYF2 in esophageal squamous cell carcinoma promotes tumor cell proliferation and predicts poor prognosis
verfasst von: Junya Zhu
Lili Ji
Jianguo Zhang
Lei Yang
Chengqi Guan
Yayun Wang
Jia Zhu
Li Liang
Runzhou Ni
Publikationsdatum: 01.10.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 10/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2305-2

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Upregulation of SYF2 in esophageal squamous cell carcinoma promotes tumor cell proliferation and predicts poor prognosis

Abstract

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Association of functional polymorphism at the miR-502-binding site in the 3′ untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report

MicroRNA-630 is a prognostic marker for patients with colorectal cancer

Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer

RETRACTED ARTICLE: Relationship of serum MMP-7 levels for colorectal cancer: a meta-analysis

Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer

Cytochrome P450 1A1 (CYP1A1) polymorphism and susceptibility to esophageal cancer: an updated meta-analysis of 27 studies

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Update Onkologie